Gout in NZ: more allopurinol and fewer NSAIDs

Goodfellow Gems Logo

Goodfellow Gems

Gout in NZ: more allopurinol and fewer NSAIDs

Gout continues to be a problem in New Zealand, particularly in Māori and Pacific populations.  In a recent paper, authors report higher use of NSAIDs in Māori and Pacific people compared with other groups, and a higher rate of hospital admission due to gout in Pacific people.1

NSAIDs are effective for control of flares but don’t lower high serum urate; at the same time, they increase the risk of CVD, gastric inflammation and kidney damage.

There has been the suggestion that preventive urate lowering medication such as allopurinol should be started after a second attack, however recent advice encourages consideration being given to starting after a first attack.2

Allopurinol must be started at a low dose of 50-100 mg (depending on renal function) and up-titrated over a few months to avoid flares and allergic reactions.3

References:

  1. Gout in Aotearoa New Zealand: the equity crisis continues in plain sight. The New Zealand Medical Journal (2018) Click here
  2. Latest guidance on the management of gout. Drug and Therapeutics Bulletin BMJ (2018) Click here
  3. Allopurinol Dosing in Renal Impairment: Walking the Tightrope Between Adequate Urate Lowering and Adverse Events. Seminars in dialysis (2007) Click here

Gems are chosen by the Goodfellow director Dr. Bruce Arroll to be either practice changing or practice maintaining. The information is educational and not clinical advice.



As published in NZ Doctor 25/09/2019